RxDoctor Payments Data

Kelsey Cowden, DO

Family Medicine · Indianapolis, INNPI 1831695071

Payments from drug & device makers

$2,124in general payments, 2019–2025

Across 123 payments — averaging $17.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$441
  • AbbVie$430
  • Lilly USA, LLC$226
  • Pfizer$164
  • AstraZeneca$143
  • Otsuka America Pharmaceutical, Inc.$136
  • plus $585 from 15 others

What the payments were for

  • Food & beverage$2,124100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,124 in reported general payments places this provider in the 70th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$26,860
Medicare patients
92
Services billed
255

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide41$54,709
MounjaroTirzepatide27$30,740
VraylarCariprazine Hcl20$30,141
JardianceEmpagliflozin18$27,485
TrulicityDulaglutide19$25,432
EliquisApixaban11$8,529
Breo ElliptaFluticasone/Vilanterol17$7,574
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$7,476
ShingrixVaricella-Zoster Ge/As01b/Pf15$3,258
Celecoxib25$2,406
Atorvastatin Calcium233$1,549
Bupropion XlBupropion Hcl41$1,254
Trazodone Hcl71$1,126
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,072
Omeprazole97$1,062

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$226$56,17246 claims
Novo NordiskOzempic$441$54,70941 claims
AbbVieVraylar$430$30,14120 claims
Boehringer IngelheimJardiance$70$27,48518 claims
GSKBreo Ellipta, Shingrix$16$10,83232 claims
PfizerEliquis$164$8,52911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →